NVCR News and Press, NovoCure Limited From 07/02/19

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended...

Establishment Labs Holdings (NASDAQ: ESTA ) initiated with Outperform rating and $29 (38% upside) price target at Wells Fargo. More news on: Establishment Labs Holdings Inc., NovoCure Limited, Avid Bioservices, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published Novocure's (NASDAQ: NVCR ) rapid report concluding that, based on a review of its EF-14 phase 3 trial, patients with newly diagnosed glioblastoma (GBM) lived longer when treated with Optune in addit...

National reimbursement decision for Optune® in Germany anticipated in 2020 Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s...

Editor's note: Seeking Alpha is proud to welcome Chen Yang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's note: Seekin...

Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without solid implementation can do more harm than good. This is especially true among growth stocks, since these ...

The following slide deck was published by NovoCure Limited in conjunction with this Read more ...

Shares of NovoCure ( NVCR ) have risen over fivefold since introducing this medical device story to readers in 2016. The stock price is up over 50% since my December update piece suggested investors take advantage of a "solid buying opportunity" caused by flat prescription growth in Q3. ...

Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a Q&A s...

The FDA approves  Novocure's (NASDAQ: NVCR ) NovoTTF-100L System, combined with Eli Lilly's (NYSE: LLY ) Alimta (pemetrexed) and platinum-based chemo, for the first-line treatment of locally advanced or metastatic malignant pleural mesothelioma (MPM). More news on: NovoCure Limited, ...